GENFLEET-B (02595) rose more than 5% intraday, and as of press time was up 3.83% at HK$20.08, with turnover of HK$10.9661 million.
On the news front, on November 16, GENFLEET-B announced that its oral pan-RAS inhibitor GFH276 has entered an Ib/II phase multicenter, open-label combination therapy study, which will be conducted at dozens of clinical sites in China and Australia. The first overseas enrolled patient was recently dosed at Monash Health in Australia, while the first enrolled patient in China was dosed in the third quarter of this year at Fudan University Shanghai Cancer Center.
According to a Late-Breaking Abstract (LBA) from this year's ESMO Annual Meeting, in the GFH276 monotherapy Phase Ia trial, as of the data cutoff date, 72.6% of patients with pancreatic ductal adenocarcinoma (PDAC) received GFH276 as third-line or later treatment, and no dose-limiting toxicities were observed at dose levels of 40-160 mg QD (patients did not use prophylactic medication). Among 61 efficacy-evaluable PDAC patients (40-160 mg QD), the overall objective response rate (ORR) was 41.1%, and the ORR was 43.1% in patients who had not previously received RAS-targeted therapy.
Comments